# Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

> **NCT01154816** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 118 (actual)

## Conditions studied

- Hepatoblastoma
- Previously Treated Childhood Rhabdomyosarcoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Kidney Neoplasm
- Recurrent Childhood Malignant Germ Cell Tumor
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma

## Interventions

- **DRUG:** Alisertib
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01154816
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2015-12-31
- **Final completion:** 2019-06-30
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2020-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154816, "Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01154816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*